La Chaux-de-Fonds, Switzerland, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces poster presentation of RP4010, a novel first-in-class SOCE inhibitor in preclinical models of Acute Myeloid Leukemia (AML).
Highlights from the poster include:
- RP4010 demonstrated single-agent activity and remarkable potentiation in activity of standard of care/approved drugs for treating AML
- RP4010 potentiated the activity of gilteritinib (XOSPATA) in reducing cell growth, induction of apoptosis, cell cycle arrest, regulation of expression of genes involved in myeloid differentiation and modulation of downstream markers
- RP4010 when combined with cytarabine (ARA-C), demonstrated significant anti-tumor activity in an MV-4-11 xenograft model
About RP4010:
RP4010 is a novel first-in-class oral small molecule inhibitor of store-operated calcium entry (SOCE) with demonstrated preclinical activity in a broad range of cancers. Blockade of SOCE through calcium release-activated calcium (CRAC) channel inhibition could suppress tumor growth via a number of downstream events including inhibition of NFAT dephosphorylation as well as calcium-dependent activation of Akt/NF-kB and ERK 1/2 pathways. A multi-center Phase I/IB dose-escalation trial evaluating the safety and efficacy of RP4010 in patients with relapsed or refractory Lymphomas is currently ongoing in USA and Australia (ClinicalTrials.gov Identifier: NCT03119467).
Details of the poster presentation:
-- Poster Title: RP4010, a small molecule inhibitor of Store-Operated Calcium Entry (SOCE), potentiates activity of Gilteritinib and Cytarabine in preclinical models of AML
- Session Title: Therapeutic Agents: Other
- Session Date: Tuesday, October 29, 2019
- Session Start Time: 12:30
- Session End Time: 16:00
- Location: Hall D, Hynes Convention Center
- Permanent Abstract No.: C045
About Rhizen Pharmaceuticals S.A.:
Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer, immune and metabolic disorders. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways. Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland. For additional information, please visit Rhizen’s website, www.rhizen.com.